Combined data for LCII and RSV illness were also greater in placebo - ( 9/101 ) than CVT-E002-treated ( 1/97 ) groups ( OR = 10.50 , P = .009 ) , for an overall 89 % relative risk reduction of ARI in the CVT-E002 group .
